Results 121 to 130 of about 1,134,125 (370)

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

open access: yesMolecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

FROM BINARIES TO MULTIPLES. II. HIERARCHICAL MULTIPLICITY OF F AND G DWARFS [PDF]

open access: yes, 2014
Statistics of hierarchical multiplicity among solar-type dwarfs are studied using the distance-limited sample of 4847 targets presented in the accompanying Paper I.
A. Tokovinin
semanticscholar   +1 more source

Four ultra-short period eclipsing M-dwarf binaries in the WFCAM Transit Survey

open access: yes, 2012
We report on the discovery of four ultra-short period ...
Allard   +83 more
core   +1 more source

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

open access: yesMolecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova   +18 more
wiley   +1 more source

THE HAWAII INFRARED PARALLAX PROGRAM. I. ULTRACOOL BINARIES AND THE L/T TRANSITION, [PDF]

open access: yes, 2012
We present the first results from our high-precision infrared (IR) astrometry program at the Canada–France–Hawaii Telescope. We measure parallaxes for 83 ultracool dwarfs (spectral types M6–T9) in 49 systems, with a median uncertainty of 1.1 mas (2.3 ...
T. Dupuy, Michael C. Liu
semanticscholar   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

open access: yesMolecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu   +12 more
wiley   +1 more source

Visual Binaries in the Orion Nebula Cluster

open access: yes, 2007
We have carried out a major survey for visual binaries towards the Orion Nebula Cluster using HST images obtained with an H-alpha filter. Among 781 likely ONC members more than 60" from theta-1 Ori C, we find 78 multiple systems (75 binaries and 3 ...
Baraffe I.   +15 more
core   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

open access: yesMolecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy